Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.

Huang, Jia-Xin; Liu, Bo; Li, Yu; Li, Xi; Ding, Li-Juan; Wang, Nan-Ya

Huang, Jia-Xin; Liu, Bo; Li, Yu; Li, Xi; Ding, Li-Juan; Wang, Nan-Ya.

Afiliação

Huang JX; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Liu B; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Li Y; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Li X; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Ding LJ; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Wang NY; Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Front Oncol ; 13: 1204486, 2023.

Article em En | MEDLINE | ID: mdl-37664019

Palavras-chave

PD-1/L1; advanced cancer; gemcitabine plus cisplatin; intrahepatic cholangiocarcinoma; lenvatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google